Get started
FERMENTA BIOTECH LIMITEDFF

FERMENTA BIOTECH LIMITED

251.50INRD
+0.25+0.10%
As of today at 04:08 GMT
INR
No trades
See on Supercharts
Overview
Financials
News Ideas Discussions Technicals Seasonals

FERMENTA fundamentals

Key facts

Market capitalization‪7.39 B‬INR
Dividend yield (indicated)0.50%
Price to earnings Ratio (TTM)20.63
Basic EPS (TTM)12.23INR
Founded1951
Employees (FY)800
CEOPrashant Prabhakar Nagre
Websitefermentabiotech.com
About

Fermenta Biotech Ltd. engages in the manufacturing and supply of Vitamin D3. It produces a range of variants such as crystalline, oil, resin in oil, cold water dispersible (CWD) and feed grade powder, which can be used in applications like injectables, soft gel capsules, premixes, as well as food and beverage fortification. The firm operates through the following segments: Chemicals/Bulk Drug and Property. The Chemicals/Bulk Drug segment engages in manufacturing and selling of chemicals, Drugs and enzymes. The property segment engages in renting of properties. The company was founded by Vijay Kumar Raju Datla on May 1, 1951 and is headquartered in Mumbai, India.

Ownership
‪‪29.43 M‬‬
Closely held shares
‪‪21.07 M‬‬ (71.61%)
Free Float shares
‪‪8.36 M‬‬ (28.39%)
Closely held shares
‪‪21.07 M‬‬ (71.61%)
Free Float shares
‪‪8.36 M‬‬ (28.39%)
Capital structure
Market cap
‪‪7.39 B‬‬
Enterprise value
‪‪7.39 B‬‬

Valuation

Fundamental metrics to determine fair value of the stock

Summary
‪‪7.39 B‬‬
Price to earning ratio (P/E)
20.63x
Price to sales ratio (P/S)
1.87x
Market Cap
Net income
Revenue
Price to earning ratio (P/E)
20.63x
Price to sales ratio (P/S)
1.87x
Valuation ratios
‪0.00‬
‪0.60‬
‪1.20‬
‪1.80‬
‪2.40‬
Q3 '23
Q4 '23
Q1 '24
Q2 '24
Q3 '24
‪0.00‬
‪30.00‬
‪60.00‬
‪90.00‬
‪120.00‬
P/E
P/S

Growth and Profitability

Company’s recent performance and margins

Performance
‪−11%‬
‪0%‬
‪11%‬
‪22%‬
‪33%‬
Q3 '23
Q4 '23
Q1 '24
Q2 '24
Q3 '24
‪‪−450.00 M‬‬
‪0.00‬
‪‪450.00 M‬‬
‪‪900.00 M‬‬
‪‪1.35 B‬‬
Revenue
Net income
Net margin %
Revenue to profit conversion
Revenue
COGS
Gross profit
Op expenses
Op income
Non-Op income/ expenses
Taxes & Other
Net income
‪0.00‬
‪‪350.00 M‬‬
‪‪700.00 M‬‬
‪‪1.05 B‬‬
‪‪1.40 B‬‬
Revenue
COGS
Gross profit
Expenses & adjustments
Net income
‪0.00‬
‪‪350.00 M‬‬
‪‪700.00 M‬‬
‪‪1.05 B‬‬
‪‪1.40 B‬‬

Revenue breakdown

Revenue streams and regions a business earns money from

By source/business
Period: 2023
Bulk Drug/Chemicals
Property
Unallocated
By country
Period: 2023
India
Other Countries
Europe
United States

Estimates

Revenue and Earnings forecasts and estimates accuracy

Revenue
Q2 '21
Q3 '21
Q4 '21
Q1 '22
Q2 '22
‪0.00‬
‪‪300.00 M‬‬
‪‪600.00 M‬‬
‪‪900.00 M‬‬
‪‪1.20 B‬‬
Estimate
Earnings
Next:Jun 2, 2025
Q2 '21
Q3 '21
Q4 '21
Q1 '22
Q2 '22
‪0.00‬
‪1.00‬
‪2.00‬
‪3.00‬
‪4.00‬
Estimate

Dividends

Dividend yield, history and sustainability

Dividend summary
10.22%
Earnings retained
Payout ratio (TTM)
Dividend yield TTM
0.50%
Last payment
1.25
Last ex-date
Aug 6, 2024
Dividend history
‪0.60%‬
‪0.75%‬
‪0.90%‬
‪1.05%‬
‪1.20%‬
2019
2020
2021
2022
2023
‪0.00‬
‪0.70‬
‪1.40‬
‪2.10‬
‪2.80‬
Dividends per share (FY)
Dividend yield (FY) %

Financial health

Financial position and solvency of the company

Debt level and coverage
Q3 '23
Q4 '23
Q1 '24
Q2 '24
Q3 '24
‪0.00‬
‪‪400.00 M‬‬
‪‪800.00 M‬‬
‪‪1.20 B‬‬
‪‪1.60 B‬‬
Debt
Free cash flow
Cash & equivalents
Financial position analysis
Short term
Long term
Assets
Liabilities